We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Tissue Probe Detects Breast Cancer Lesion Margins

By HospiMedica International staff writers
Posted on 17 Jan 2013
An innovative device assists surgeons performing breast lumpectomies to confirm the removal of the entire tumor.

The MarginProbe System uses electromagnetic "signatures" to identify healthy and cancerous breast tissue, taking advantage of the fact that cancerous tissue--while often similar in form to the healthy counterpart that it evolved from--has a greater density of vasculature. More...
This difference can be identified by transmitted electrical pulses through the tissue and measurement of the returning electromagnetic response of the tissue, which is attenuated in distinct ways by tumors. With an indication of cancerous cells at the margins, the surgeon can then excise additional tissue during the surgical procedure, saving time and, potentially, a second procedure.

The head of the disposable probe unit houses the proprietary Fringe Field Sensor (FFS), which runs a series of measurements on each margin, collecting data for the entire specimen. The external console unit houses proprietary software that captures the signal and compares it to an internal database, reporting results on the high-resolution display. The display lists each reading sequentially, which allows for grouping measurements from the same margin, allowing the surgeon to track progress and identify problem areas. The MarginProbe System is a product of Dune Medical Devices (Caesarea, Israel), and has been approved by the US Food and Drug Administration (FDA).

“The MarginProbe System was developed to address one of the longest standing unmet medical needs in the breast cancer surgical community,” said Daniel Levangie, CEO of Dune Medical Devices. “We have received resounding support from clinicians, advocacy organizations and patients alike, who have recognized the value of MarginProbe and intraoperative, real-time detection of cancer on the margin to potentially improve patient outcomes.”

Breast lumpectomy is a common surgical procedure designed to remove a discrete lump, usually a benign tumor or breast cancer, from an affected breast. As the tissue removed is generally quite limited and the procedure relatively noninvasive, compared to a mastectomy, a lumpectomy is considered a viable means of breast conservation surgery with all the attendant physical and emotional advantages of such an approach. Lumpectomy may be performed for ductal carcinoma in situ (DCIS), for invasive ductal carcinoma, or for other conditions.

Related Links:
Dune Medical Devices


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.